EUVIMEDEUVIMED entdecken
Crossref

Metastatic primary breast neuroendocrine neoplasms: a case series

Kathleen Batty iD, Amelia M Taylor, Elizabeth J Bernard, Connie I Diakos, Stephen J Clarke, Alexander Guminski, Sally Baron-Hay, Frances Boyle, Nick Pavlakis, David L Chan

Internal Medicine Journal · 2023-10 · 53 (10) · 1813-1818

DOI: 10.1111/imj.15961 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 31.10.2022. Verfasst von Kathleen Batty und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Breast Neoplasms, Carcinoma, Neuroendocrine, Neoplasms, Second Primary. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast neuroendocrine neoplasms represent a rare subtype of breast cancer which have not been well studied or characterised, particularly in the metastatic setting.

Aim

To present clinicopathological characteristics, treatment and outcomes of a series of patients with metastatic neuroendocrine carcinoma of the breast and review the current literature.

Methods

We performed a retrospective review to identify and describe patients with metastatic neuroendocrine carcinoma of the breast at our centre between 2011 and 2021. Medical records, pathology and imaging results were examined to evaluate the clinical and histopathological features as well as the treatment pathways and prognosis of these patients.

Results

We present a series of seven female patients with metastatic neuroendocrine carcinoma of the breast, as defined by the World Health Organization classification, over a period of 10 years (2011–2021) from a single centre. Median age at diagnosis was 48 years (range 39–63). Six of seven tissue samples expressed synaptophysin and chromogranin and were also oestrogen and progesterone receptor positive; median Ki‐67 index was 50% (range 20–90%). All seven patients had demonstrated avidity on 18 F‐FDG PET imaging, and the six who underwent 68 Ga‐DOTATATE PET all had significant avidity. Treatment modalities and sequencing varied, but all patients received chemotherapy during their disease course. Six patients received three or more lines of treatment. Median overall survival was 31.8 months (range 3.7–108.6). Median progression‐free survival (PFS) with first‐line therapy for metastatic disease was 5.8 months (range 1.8–37.8).

Conclusions

This series shows the use of multiple modalities in treating this disease, with different sequencing in different patients. Despite multiple modalities used in the first‐line setting, first‐line PFS remains short. Larger series and further molecular characterisation are required to aid clinicians in managing this condition and to guide optimal treatment sequencing to improve outcomes in this rare patient group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsBreast NeoplasmsCarcinoma, NeuroendocrineNeoplasms, Second PrimaryHumansFemaleAdultMiddle AgedPrognosisFluorodeoxyglucose F18Retrospective Studies

Stichwörter der Autor:innen

breast carcinomabreast neoplasmscancer of the breastmalignant neoplasmneuroendocrine tumour

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.
  • Patricia Ritchie Centre for Breast Cancer Research, Mater Hospital, North Sydney and University of Sydney, The Mater Hospital, Sydney, New South Wales, Australia.
  • University of Sydney, Sydney, Australia.

ORCID-Profile: Kathleen Batty

Zitieren

APA

Batty, K., Taylor, A. M., Bernard, E. J., Diakos, C. I., Clarke, S. J., Guminski, A., Baron-Hay, S., Boyle, F., Pavlakis, N., & Chan, D. L. (2023). Metastatic primary breast neuroendocrine neoplasms: a case series. Internal Medicine Journal, 53(10), 1813-1818. https://doi.org/10.1111/imj.15961

Vancouver

Batty K, Taylor AM, Bernard EJ, Diakos CI, Clarke SJ, Guminski A, et al. Metastatic primary breast neuroendocrine neoplasms: a case series. Internal Medicine Journal. 2023;53(10):1813-1818. doi:10.1111/imj.15961

BibTeX
@article{Batty2023,
  author = {Batty, Kathleen and Taylor, Amelia M and Bernard, Elizabeth J and Diakos, Connie I and Clarke, Stephen J and Guminski, Alexander and Baron-Hay, Sally and Boyle, Frances and Pavlakis, Nick and Chan, David L},
  title = {Metastatic primary breast neuroendocrine neoplasms: a case series},
  journal = {Internal Medicine Journal},
  year = {2023},
  volume = {53},
  number = {10},
  pages = {1813--1818},
  doi = {10.1111/imj.15961}
}
Kostenlos starten →